My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: Merck MODIFY II MK-3415A
Title:

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to Clostridium difficile toxin B) and MK-3415A (Human Monoclonal Antibodies to Clostridium difficile toxin A and toxin B) in Patients Receiving Antibiotic Therapy for Clostridium difficile Infection

Description:

MK-3415 (fully human monoclonal antibody to toxin A only) will not be tested alone in this study but will be used in combination with MK-6072 to make up MK-3415A (the combination of fully human monoclonal antibody to C. difficile toxin A [MK-3415] and fully human monoclonal antibody to C. difficile toxin B [MK-6072]. A separate Phase III study (Protocol 001, also known as MODIFY I) is evaluating the efficacy and safety of MK-3415. The primary goal of this clinical program is to show that a single intravenous infusion of MK-3415A (10 mg/kg of each monoclonal antibody to C. difficile toxin A [MK-3415] and toxin B [MK-6072]) reduces recurrence of C. difficile infection (CDI).

Location:
Fargo Region, Sioux Falls Region
Principal Investigator:
Srividya Srinivasan MD,Paul Mariani MD
Disease:
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list